TEVA
Teva Pharmaceutical Industries Limited
NYSE · ILHealthcareDrug Manufacturers - Specialty & Generic
$31.00-3.22%
Price as of Jul 20, 2026
TEVA financials
Teva Pharmaceutical Industries Limited financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $17.3B | $16.5B | $15.8B | $14.9B |
| Cost of revenue | $8.3B | $8.5B | $8.2B | $8.0B |
| Gross profit | $8.9B | $8.1B | $7.6B | $7.0B |
| Operating expenses | $6.8B | $8.4B | $7.2B | $9.2B |
| Operating income | $2.2B | -$303.0M | $433.0M | -$2.2B |
| Net income | $1.4B | -$1.6B | -$559.0M | -$2.4B |
| EBITDA | $3.1B | $4.4B | $1.6B | -$925.0M |
| Basic EPS | $1.23 | $-1.45 | $-0.50 | $-2.20 |
| Diluted EPS | $1.20 | $-1.45 | $-0.50 | $-2.20 |
| Balance sheet | ||||
| Cash & equivalents | $3.6B | $3.3B | $3.2B | $2.8B |
| Total assets | $40.7B | $39.3B | $43.5B | $44.0B |
| Total liabilities | $32.8B | $33.6B | $35.4B | $35.4B |
| Stockholders’ equity | $7.9B | $5.4B | $7.5B | $7.8B |
| Total debt | $17.4B | $18.1B | $20.2B | $21.6B |
| Net debt | $13.8B | $14.8B | $16.9B | $18.8B |
| Cash flow | ||||
| Operating cash flow | $1.6B | $1.2B | $1.4B | $1.6B |
| Capital expenditure | -$501.0M | -$498.0M | -$526.0M | -$548.0M |
| Free cash flow | $1.1B | $749.0M | $842.0M | $1.0B |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |